Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Biomarin Pharmaceutical Inc(BMRN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BMRN
11/05/2026: BMRN (1-star) is currently NOT-A-BUY. Pass it for now.
BioMarin Pharmaceutical Inc is a specialized biotechnology company focused on developing and commercializing therapies for serious, rare genetic diseases. Its main strength lies in a proven track record of bringing orphan drugs to market, with the recent success of Voxzogo acting as a major growth engine. The company’s primary opportunity remains expanding the global reach of its existing portfolio and pipeline assets. However, investors must weigh these prospects against risks like high R&D costs, intense competition in the gene therapy space, and potential pricing pressure. BioMarin may suit growth-oriented investors, though careful monitoring of clinical milestones and commercial execution is essential.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | BioMarin's focus on high-growth rare disease therapies targets significant market opportunities. |
| Momentum investor | Mixed fit | Momentum is conditional on positive clinical milestones and sales growth signals. |
| Value investor | Weak fit | The company's valuation is primarily driven by future pipeline potential rather than current earnings multiples. |
| Dividend investor | Weak fit | The company does not pay dividends, focusing instead on reinvesting in R&D. |
| Low-risk investor | Weak fit | Biotechnology investments, especially those focused on clinical trials, involve inherent high volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical, regulatory, and commercial news. |
| Valuation risk | Medium / high | High premiums are often baked in due to long-term growth expectations. |
| Competition risk (rare disease and gene therapy) | Medium / high | Rapid innovation in genetic medicine can quickly challenge existing therapies. |
| Business quality | Medium | The company has strong technical capabilities but operates in a high-cost, high-risk sector. |
| Dividend income | Low / none | Income investors should not look here for yield. |
| Execution risk | High | Success relies heavily on meeting complex regulatory and commercial launch milestones. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit -29.75% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.06B USD | Price to earnings Ratio - | 1Y Target Price 91.04 |
Price to earnings Ratio - | 1Y Target Price 91.04 | ||
Volume (30-day avg) 2.5M shares | Beta 0.23 | 52 Weeks Range 49.26 - 70.98 | Updated Date 11/05/2026 |
52 Weeks Range 49.26 - 70.98 | Updated Date 11/05/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.1 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Metabolic & Genetic Products | Revenue from products like Voxzogo and Palynziq. | BioMarin sells specialized, high-priced drugs for rare diseases. |
| Gene Therapy | Revenue from Roctavian and development stage candidates. | This segment is focused on long-term growth through advanced genetic medicine. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-02 | When After Market | Estimate -0.3 | Actual 0.02 |
Profitability
Profit Margin -0.52% | Operating Margin (TTM) 26.41% |
Management Effectiveness
Return on Assets (TTM) 3.77% | Return on Equity (TTM) -0.31% |
Valuation
Trailing PE - | Forward PE 8.45 | Enterprise Value 14.52B | Price to Sales(TTM) 3.03 |
Enterprise Value 14.52B | Price to Sales(TTM) 3.03 | ||
Enterprise Value to Revenue 4.14 | Enterprise Value to EBITDA 36.58 | Shares Outstanding 193.68M | Shares Floating 192.73M |
Shares Outstanding 193.68M | Shares Floating 192.73M | ||
Percent Insiders 0.34 | Percent Institutions 103.09 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.